Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 897

Sort by

Sort Order Select

Journal Articles

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

Thura Win Htut, MBBS, MRCP, Kyaw Zin Thein, MDMBBS, Anita Sultan, MD, Sriman Swarup, MDMBBS, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Sanjay Awasthi, MD, Akshar Dash, Myat Min Han, MD, Yin Mon Myat, MD, Fred Hardwicke, MD, Lukman Tijani, MD, Nicholas D'Cunha, MD, Donald P. Quick, MD

Blood (2019) 134 (Supplement_1): 3485.

https://doi.org/10.1182/blood-2019-123145

Published: 2019

Journal Articles

Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?

Margaret Diguardo, MD, Scott Hammel, Kate Heaser, Victor Mahaffey, Christopher Hofich, Sarah Kester, Sarah Kerr, MD, Jennifer L. Oliveira, MD, Eapen K. Jacob, MD, Ann Moyer, MD

Blood (2019) 134 (Supplement_1): 3698.

https://doi.org/10.1182/blood-2019-128576

Published: 2019

Journal Articles

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Motoo Nagane, MD PhD, Yoshitaka Narita, MD PhD, Kazuhiko Mishima, MD PhD, Yasuhito Terui, MD PhD, Yoshiki Arakawa, MD PhD, Hajime Yonezawa, MD PhD, Katsunori Asai, MD PhD, Noriko Fukuhara, MD PhD, Kazuhiko Sugiyama, MD PhD, Naoki Shinojima, MD PhD, Junsaku Kitagawa, Arata Aoi, Ryo Nishikawa, MD PhD

Blood (2019) 134 (Supplement_1): 1586.

https://doi.org/10.1182/blood-2019-123362

Published: 2019

Journal Articles

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Hassan Awada, MD, Jibran Durrani, Tariq Zuheir Kewan, MD, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 1404.

https://doi.org/10.1182/blood-2019-131724

Published: 2019

Journal Articles

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

Daniel Heudobler, Sebastian Klobuch, MD, Florian Lüke, MD, Joachim Hahn, MD, Matthias Grube, MD, Stephan Kremers, MD, Thomas Südhoff, MD, Jörg Westermann, MD, Marie-Luise Huetter-Kroenke, MD, Peter Paschka, MD, Gauthier Bouche, Hartmut Döhner, MD, Wolfgang Herr, MD, Simone Thomas, MD, Albrecht Reichle, MD

Blood (2019) 134 (Supplement_1): 1382.

https://doi.org/10.1182/blood-2019-129977

Published: 2019

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Arafat Ali Farooqui, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Saad Farooqi, MD, Maimoona Khan, MBBS, Aqsa Ashraf, MD, Ahmad Anjum, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5546.

https://doi.org/10.1182/blood-2019-121999

Published: 2019

Journal Articles

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Arafat Ali Farooqui, MD, Ahmad Anjum, MD, Muhammad Saad Farooqi, MD, Talha Bin Farooq, MD, Tanveer Shaukat, MD, Aqsa Ashraf, MD, Humaira Sarfraz, MD, Zunairah Shah, MBBS, Muhammad Junaid Tariq, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5548.

https://doi.org/10.1182/blood-2019-122395

Published: 2019

Journal Articles

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Blood (2019) 134 (Supplement_1): 463.

https://doi.org/10.1182/blood-2019-127811

Published: 2019

Journal Articles

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Blood (2019) 134 (Supplement_1): 696.

https://doi.org/10.1182/blood-2019-127954

Published: 2019

Journal Articles

Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias

Daichi Inoue, MD PhD, Stanley C Lee, PhD, Akihide Yoshimi, MD PhD, Justin Taylor, MD, Lillian E Bitner, BSc, Atsushi Tanaka, MD, Yasutaka Hayashi, MD PhD, Hana Cho, MSc, Chie Fukui, Ruth Saganty, Alexander V Penson, PhD, Omar Abdel-Wahab, MD

Blood (2019) 134 (Supplement_1): 917.

https://doi.org/10.1182/blood-2019-124722

Published: 2019

Journal Articles

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Aneel Paulus, MD, Victoria R. Alegria, Betsy Laplant, MS, Muhamad Alhaj Moustafa, MD, Dustin Chapin, Keisha Jackson, Prachi Jani, MD, Salman Ahmed, MD, Brett Edwards, Alak Manna, PhD, Vivek Roy, MD, Taimur Sher, MD, Asher A. Chanan-Khan, MD

Blood (2019) 134 (Supplement_1): 1912.

https://doi.org/10.1182/blood-2019-128233

Published: 2019

Journal Articles

Secondary Autoimmune Neutropenia: Data from the Italian Neutropenia Registry

Francesca Fioredda, PhD, Piero Farruggia, Andrea Beccaria, Antonino Trizzino, LuciaDora Notarangelo, Tiziana Lanza, Andrea Rotulo, Isabella Ceccherini, Angela Guarina, Alice Grossi, Federico Verzegnassi, Elena Mastrodicasa, Laura Luti, Angelica Barone, Giovanna Russo, Laura Porretti, Marta Pillon, Maurizio Miano, Carlo Dufour

Blood (2019) 134 (Supplement_1): 3585.

https://doi.org/10.1182/blood-2019-126526

Published: 2019

Journal Articles

RASA3 Is Essential for Early Mammalian Hematopoiesis and Modulates ERK Signaling in Terminal Erythropoiesis

Elena C. Brindley, BS, Raymond F. Robledo, PhD, Steven L. Ciciotte, MS, Joel H. Graber, PhD, Yue Zhao, Emily Hartman, BS, Julien Papoin, MS, Lionel Blanc, PhD, Luanne L. Peters, PhD

Blood (2019) 134 (Supplement_1): 3505.

https://doi.org/10.1182/blood-2019-130328

Published: 2019

Journal Articles

Autologous Hematopoietic Stem Cell Infusion for Myelosuppression after Bcma-CART Therapy in Relapsed Myeloma Patients

Quande Lin, PhD, Lu Han, MS, Jian Zhou, MD PhD, Lina Liu, Master, Yuzhang Liu, master, Fengkuan Yu, Master, YangLi Zhang, Master, Wenli Zuo, Doctor, Keshu Zhou, MD, Baijun Fang, MD, Quanli Gao, Doctor, Xudong Wei, PhD, Delong Liu, MD PhD, Yongping Song, MD PhD

Blood (2019) 134 (Supplement_1): 1851.

https://doi.org/10.1182/blood-2019-128410

Published: 2019

Journal Articles

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Georgina S. Daher-Reyes, MD, Isabelle Bence-Bruckler, MD, Lambert Busque, MD, Donna L. Forrest, MD, Lynn Savoie, MD, Mary-Margaret Keating, MD, Robert Delage, MD, Anargyros Xenocostas, MD FRCPC, Elena Liew, MDBSc,FRCPC, Pierre Laneuville, MD FRCPC, Kristjan Paulson, MD, Jeffrey H. Lipton, MD PhD, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Brian Leber, MD, Dennis Dong Hwan Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1653.

https://doi.org/10.1182/blood-2019-131599

Published: 2019

Journal Articles

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Partow Kebriaei, MD, Pinaki P Banerjee, PhD, Christina Ganesh, BSN, RN, Mecit Kaplan, MS, Vandana Nandivada, BS, MS, Ana Karen Nunez Cortes, MD, Amin M. Alousi, MD, David Marin, MD, Elizabeth J. Shpall, MD, Rohtesh Mehta, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Katayoun Rezvani, MD PhD

Blood (2019) 134 (Supplement_1): 1298.

https://doi.org/10.1182/blood-2019-125931

Published: 2019

Journal Articles

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Yuankai Shi, MD, Lin Gui, MD, Junning Cao, MD, Huilai Zhang, MD, Jun Zhu, MD PhD, Dongmei Ji, MD PhD, Qian Fan, MD, Yuqin Song, MD PhD, Weina Shen, MM, Guiying Bai, MM, Ming-Zhe Han, MD, Shiyu Jiang

Blood (2019) 134 (Supplement_1): 2840.

https://doi.org/10.1182/blood-2019-128078

Published: 2019

Journal Articles

Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study

Xinran Ma, MSc, Ling Li, Lei Zhang, Xin Li, Xiaorui Fu, Xinhua Wang, PhD, Jingjing Wu, Xudong Zhang, Xiaoyan Feng, Zhiyuan Zhou, Yu Chang, Zhaoming Li, MD PhD, Ken H. Young, Mingzhi Zhang

Blood (2019) 134 (Supplement_1): 2873.

https://doi.org/10.1182/blood-2019-127912

Published: 2019

Journal Articles

Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Blood (2019) 134 (Supplement_1): 4036.

https://doi.org/10.1182/blood-2019-129305

Published: 2019

NARROW

Daratumumab-Related Hematological Toxicities in Patients with Multiple Myeloma: A Combined Analysis of Five Phase III Randomized Controlled Trials

Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?

Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Low-Dose Azacitidine, Pioglitazone and All-Trans Retinoic Acid Versus Standard-Dose Azacitidine in Patients ≥ 60 Years with Acute Myeloid Leukemia Refractory to Standard Induction Chemotherapy (AMLSG 26-16/AML-ViVA): Results of the Safety Run-in Phase I

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Antibody Based Three-Drug Regimens for Multiple Myeloma - a Systematic Review of Phase II and Phase III Clinical Trials

Efficacy of Elotuzumab Based Combinations in Patients with Multiple Myeloma - a Systematic Review

Efficacy and Survival in Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized, Controlled, Multicenter and Open-Labled Study with Ddgp Regimen Versus SMILE Regimen

Carfilzomib-Revlimid-Dexamethasone Vs. Carfilzomib-Thalidomide-Dexamethasone Weekly (After 2 Twice Weekly Cycles) Followed By Carfilzomib Maintenance Vs. Control in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) - Interim Efficacy Analysis of Combined Data (AGMT MM-02)

Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias

Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Secondary Autoimmune Neutropenia: Data from the Italian Neutropenia Registry

RASA3 Is Essential for Early Mammalian Hematopoiesis and Modulates ERK Signaling in Terminal Erythropoiesis

Autologous Hematopoietic Stem Cell Infusion for Myelosuppression after Bcma-CART Therapy in Relapsed Myeloma Patients

Comprehensive Analysis of Hematological Parameter Changes after TKI Discontinuation for Treatment-Free Remission Attempt

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

A Phase 1b/2 Study of Chidamide Combined with CHOP in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL)

Efficacy and Safety of Apatinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: An Open-Label, Single-Arm, Prospective Study

Combination of Chidamide with the CHOEP Regimen in Previously Untreated Patients with Peripheral T-Cell Lymphoma (PTCL): A Prospective, Multicenter, Single-Arm, Phase 1b/2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only